Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
Coste ATInstitute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Kritikos AService of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Li JInstitute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Khanna NDivision of Infectious Diseases and Hospital Epidemiology, University and University Hospital of Basel, Basel, Switzerland.
Goldenberger DDivision of Clinical Bacteriology and Mycology, University and University Hospital of Basel, Basel, Switzerland.
English
Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.